Veru Inc.

Veru Announces Clinical Supply Agreement with Novo Nordisk for Phase 2b PLATEAU Study.

“We appreciate Novo Nordisk providing Wegovy® clinical supply for our Phase 2b PLATEAU study. The study will evaluate the use of enobosarm, an investigational therapy, in combination with a GLP‑1 receptor agonist in older patients with obesity to explore its potential impact on weight loss, body composition and physical function over 68 weeks,” said Mitchell Steiner, M.D., Chairman, President and Chief Executive Officer of Veru.

Novo Nordisk provides Wegovy® solely for use within the study under a clinical supply agreement. Please see our 8‑K filing for further details.

ir.verupharma.com

Veru was featured in The Athletic, a New York Times company, in an article examining GLP-1s, muscle loss, and the evolving debate around performance enhancement in sports.

The article highlights a key issue in GLP-1 weight loss: muscle loss. Veru is working to address this clinical challenge through enobosarm as an adjunctive therapy with GLP-1 drugs to help preserve lean muscle.

Veru’s CEO, Dr. Mitchell Steiner, was quoted in the article discussing enobosarm.

Serena Williams and the coming reckoning with GLP-1s and performance enhancement GLP-1s are not prohibited; the way they work means they might never be. Anti-doping authorities are still monitoring how athletes use them.

https://ir.verupharma.com/news-events/press-releases/detail/254/veru-reports-fiscal-2026-second-quarter-financial-results

Veru Reports Fiscal 2026 Second Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress --Phase 2b PLATEAU clinical study evaluating enobosarm + semaglutide is actively enrolling and on track for interim analysis first quarter…...

https://ir.verupharma.com/news-events/press-releases/detail/253/veru-to-report-fiscal-2026-second-quarter-financial-results

Veru to Report Fiscal 2026 Second Quarter Financial Results on May 13th MIAMI, FL, May 06, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on…...

https://ir.verupharma.com/news-events/press-releases/detail/252/veru-enrolls-first-patient-in-phase-2b-plateau-clinical

Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss -- The Phase 2b study to assess enobosarm’s ability to preserve lean mass, physical function, and bone as well as burn more fat to produce…...

https://ir.verupharma.com/news-events/press-releases/detail/251/veru-to-present-at-the-oppenheimer-36th-annual-healthcare

Veru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference MIAMI, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing…...

https://ir.verupharma.com/news-events/press-releases/detail/250/veru-reports-fiscal-2026-first-quarter-financial-results

Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress -- Phase 2b PLATEAU clinical trial evaluating enobosarm in combination with semaglutide in older patients with obesity on track to initiate…...

https://ir.verupharma.com/news-events/press-releases/detail/249/veru-to-report-fiscal-2026-first-quarter-financial-results

Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th MIAMI, FL, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on…...

https://ir.verupharma.com/news-events/press-releases/detail/248/veru-reports-fiscal-year-2025-financial-results-and

Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress -- Following positive efficacy and safety results from Phase 2b QUALITY study, company received FDA regulatory clarity for enobosarm in…...

https://ir.verupharma.com/news-events/press-releases/detail/247/veru-to-report-fiscal-year-2025-financial-results-on

Veru to Report Fiscal Year 2025 Financial Results on December 17th MIAMI, FL, Dec. 10, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on…...